洛拉替尼治疗期间发生糖尿病酮症酸中毒:病例报告
本文报告一例65岁男性间变性淋巴瘤激酶阳性肺癌合并2型糖尿病患者,从阿来替尼换用洛拉替尼后发生糖尿病酮症酸中毒,糖化血红蛋白三个月内从6%升至11.5%。经停用洛拉替尼并强化胰岛素治疗后酮症酸中毒缓解,中断2周后以减量恢复洛拉替尼,血糖控制满意。病例提示接受洛拉替尼治疗者需警惕血糖监测。
要点
- 洛拉替尼相关高血糖较少见但可能危及生命
- 合并糖尿病者换用洛拉替尼后血糖可迅速恶化
- 本例糖化血红蛋白三个月内从6%升至11.5%
核心结论
- 本病例提示接受洛拉替尼治疗的患者,尤其合并糖尿病者,需警惕血糖监测以预防糖尿病酮症酸中毒等危及生命的并发症。
研究设计与样本
- 本文为病例报告,对象为一名65岁男性间变性淋巴瘤激酶阳性肺癌合并2型糖尿病患者。
主要发现
- 患者从阿来替尼换用洛拉替尼后血糖控制迅速恶化,糖化血红蛋白三个月内从6%升至11.5%。
- 患者因糖尿病酮症酸中毒入院,接受强化胰岛素治疗并暂时停用洛拉替尼后酮症酸中毒缓解。
- 中断2周后以减量恢复洛拉替尼,血糖控制满意。
临床怎么用
- 作者强调对接受洛拉替尼治疗的患者,尤其合并糖尿病者,应保持警惕的血糖监测以预防糖尿病酮症酸中毒等危及生命的并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although hyperlipidemia is a well-known adverse event associated with lorlatinib treatment, lorlatinib-associated hyperglycemia is less common but can be potentially life-threatening. We present the case of a 65-year-old male patient with anaplastic lymphoma kinase-positive lung cancer and preexisting type 2 diabetes mellitus who developed diabetic ketoacidosis (DKA) after switching from alectinib to lorlatinib. After initiating lorlatinib treatment, the patient's glycemic control deteriorated rapidly, with the glycated hemoglobin levels increasing from 6% to 11.5% within three months. The patient was admitted and received intensive insulin therapy along with temporary discontinuation of lorlatinib, which successfully resolved DKA. After a 2-week interruption, lorlatinib was resumed at a reduced dose with satisfactory glycemic control. This case highlights the importance of vigilant glucose monitoring for patients receiving lorlatinib, especially those with preexisting diabetes, to prevent life-threatening complications such as DKA.
引用
- Yanagisawa A, Shiroyama T, Miyake K, et al. Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report. J Thorac Oncol. 2025. PMID: 39891649. doi:10.1016/j.jtho.2025.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。